Thus, we raised awareness of the mild clinical picture of ARCS, and we propose that molecular analysis of the VPS33B and VIPAS39 should be considered in patients with normal GGT cholestasis, and not only for patients with the complete ARCS phenotype. This evidence concerns the gene VPS33B and cholestasis.